Advertisement

Topics

ImmuPharma says 90% of patients have pass six-month milestone on key lupus trial

03:19 EDT 30 Jun 2017 | Proactive Investors

ImmuPharma PLC (LON:IMM) said more than 90% of the patients on its phase III clinical study of Lupuzor, for the autoimmune disease lupus, six months through the process. In all 200 suffers were recruited to the trial and all of them have now past the three month stage. A total of 46 patients, or just under a quarter, have completed the year-long assessment, while 40% have passed nine-months. ImmuPharma said it remains on track to provide top-line results in the first quarter of next year. The data was provided ahead of an investor update to be held in London that will be coupled with the company’s annual meeting later Friday. “As the trial continues to progress, we are delighted to observe the continuation of our robust safety record, as Lupuzor is being administered to greater numbers of patients over a longer period of time,” chairman Tim McCarthy said.

Original Article: ImmuPharma says 90% of patients have pass six-month milestone on key lupus trial

NEXT ARTICLE

More From BioPortfolio on "ImmuPharma says 90% of patients have pass six-month milestone on key lupus trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...